Abbott i-STAT 1 System Manual

Rev. Date: 23-May-12 Art: 716969-00J BNP - 15
18. Doust JA, Petrzak E, Dobson A, Glasziou P. How Well Does B-Type Natriuretic Peptide Predict Death
and Cardiac Events in Patients With Heart Failure: Systematic Review. BMJ. 2005 Mar 19; 330(7492):
625.
19. Anand IS, Fisher LD, Chiang Y-T, Latini R, Masson S, Maggioni AP, et al. Changes in Brain Natriuretic
Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial
(Val-HeFT). Circulation. 2003 Mar 11; 107(9): 1278-83.
20. Richards AM, Nicholls MG, Yandle TG, Ikram H, Espiner EA, Turner JG, et al. Neuroendocrine Predic-
tion of Left Ventricular Function and Heart Failure After Acute Myocardial Infarction. Heart. 1999 Feb;
81(2): 114-20.
21. Richards AM, Nicholls MG, Espiner EA, et al. B-Type Natriuretic Peptides and Ejection Fraction For
Prognosis After Myocardial Infarction. Circulation. 2003 Jun 10; 107(22): 2786-92.
22. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of
diseases of the heart and great vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994: 253-6.
23. Wieczorek SJ, Wu AHB, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diag-
noses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002, 144(5):
834-9.
24. American Heart Association. 2000 Heart and Stroke Statistical Update. Dallas, TX: American Heart As-
sociation; 1999: 18-19.
25. MacKay AP, Fingerhut LA, Duran CR. Adolescent Health Chartbook. Health, United States, 2000. Hy-
attsville, MD: National Center for Health Statistics; 2000: 123.
26. Clinical and Laboratory Standards Institute (CLSI). Method Comparison and Bias Estimation Using Pa-
tient Samples; Approved Guideline – Second Edition. CLSI document EP9-A2 [ISBN 1-56238-472-4].
Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania
19087-1898, USA 2002.
27. P.J. Cornbleet and N. Gochman, “Incorrect Least-Squares Regression Coefficients in Method-Compari-
son Analysis,” Clinical Chemistry 25:3, 432 (1979).
28. Clinical and Laboratory Standards Institute (CLSI). Immunoassay Interference by Endogenous
Antibodies; Proposed Guidelines. CLSI document I/LA30-P (ISBN 1-56238-633-6) Clinical and
Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-
1898 USA, 2007.
29. Bjerner et al. Immunometric Assay Interference: Incidence and Prevention. Clin. Chem. 2002;
48:613.
30. Kricka, Interferences in Immunoassays - Still a Threat. Clin. Chem. 2000; 46:1037.
31. Schroff et al. Human anti-murine immunoglobulin responses in patients receiving monoclonal
antibody therapy. Cancer Res. 1985; 45:879.
32. Primus et al. “Sandwich”-type immunoassay of carcinoembryonic antigen in patients receiving
murine monoclonal antibodies for diagnosis and therapy. Clin. Chem. 1988; 34-261.
33. Nahm et al. Heteroantibody: phantom of the immunoassay. Clin. Chem. 1990; 36:829.
34. Boscato et al. Heterophilic antibodies: a problem for all immunoassays. Clin Chem. 1988; 34:27.
35. Maisel AS, Cremo R, Gardetto N, et al. [The effects of nesiritide on serum levels of B-type
natriuretic peptide (BNP) in patients admitted for decompensated conjestive heart failure [Abstr].]
Circulation (suppl II), 106:19, 565 (2002).
36. Clinical and Laboratory Standards Institute (CLSI). Interference Testing in Clinical Chemistry;
Approved Guideline. CLSI document EP7-A [ISBN 1-56238-480-5]. Clinical and Laboratory
Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA
2002.

Abbott i-STAT 1 Specifications

General

Brand	Abbott
Model	i-STAT 1
Category	Measuring Instruments
Language	English